Top Markets
Coin of the day
Fennec Pharmaceuticals Inc. Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENC
Rang in Aktien #14216
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading... Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Aktienkurs
$12.33
Zuletzt synchronisiert: 2026-08-31
Marktkapitalisierung
$428.31M
Veränderung (1 Tag)
0.49%
Veränderung (1 Jahr)
39.01%
Land
US
Handel Fennec Pharmaceuticals Inc. (FENC)

Kategorie

Dividendenrendite-Verlauf für Fennec Pharmaceuticals Inc. (FENC)
Dividendenrendite (TTM) von Fennec Pharmaceuticals Inc. (Aktienkürzel: FENC) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Fennec Pharmaceuticals Inc. (FENC) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH